GENE ONLINE|News &
Opinion
Blog

Breast Cancer
Novartis’ CDK4/6 Inhibitor Meets Phase 3 Endpoints In Breast Cancer
2023-03-28
Menarini’s Oral SERD Gains First-Ever FDA Approval for Breast Cancer
2023-01-30
Action Date Set for Gilead Sciences’ HR+/HER2- breast cancer sBLA
2022-10-11
Roche’s Newly Approved Companion Diagnostic May Open Treatment Options for HER2-low Patients
2022-10-06
AstraZeneca and Merck’s HER2-negative Breast Cancer Treatment Wins Yet Another Approval
2022-08-25
Sanofi Abandons SERD Candidate After Second Breast Cancer Clinical Trial Blow
2022-08-18
Gilead Forking Over $280 million to Everest to Regain Rights to Breast Cancer Treatment
2022-08-16
Gilead’s New Chemotherapy for Metastatic Breast Cancer Demonstrates Increase in Overall Survival
2022-08-15
First Targeted Therapy for HER2-Low Breast Cancer Approved by FDA
2022-08-05
Amazon, Fred Hutchinson Begin Human Trial for Cancer Vaccine
2022-07-14
Organon Licenses Biosimilars From Shanghai’s Henlius For $103 Million
2022-06-14
Everest Medicines Secures Breast Cancer Drug Approval in China
2022-06-13
ASCO 2022: AstraZeneca, Pfizer, Novartis Share Key Data on Breast Cancer Therapeutics
2022-06-07
Everest and Gilead Announce Positive Phase 3 Results of Breast Cancer Drug
2022-06-06
EU Expands Merck’s Keytruda Use on Breast Cancer
2022-05-25
1 2 3 4
LATEST
Ginkgo Bioworks and Pfizer Forge $331 Million Collaboration for RNA-Based Drug Discovery
2023-09-29
Johnson & Johnson Partners with Singapore to Boost Life Sciences Innovation
2023-09-28
Vietnam and South Korea Strengthen Cooperation in Multiple Sectors
2023-09-27
PeptiDream and Genentech Collaborate on Novel Peptide-Radioisotope Drug Conjugates
2023-09-27
AcuraStem and Takeda Collaborate on Innovative ALS Treatment
2023-09-27
Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report
2023-09-27
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
EVENT
2023-10-04
BioFuture 2023
New York city,USA
Scroll to Top